These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26894601)

  • 1. Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling.
    Guo L; Zhou B; Liu Z; Xu Y; Lu H; Xia M; Guo E; Shan W; Chen G; Wang C
    Tumour Biol; 2016 Aug; 37(8):11007-15. PubMed ID: 26894601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
    Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
    Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
    Jin HO; Lee YH; Park JA; Kim JH; Hong SE; Kim HA; Kim EK; Noh WC; Kim BH; Ye SK; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK
    Biochem Biophys Res Commun; 2014 Feb; 444(4):502-8. PubMed ID: 24472538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
    Masamha CP; LaFontaine P
    J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
    Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
    J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
    Gordeev SA; Bykova TV; Zubova SG; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
    Oncotarget; 2015 Dec; 6(42):44905-26. PubMed ID: 26636543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutaminolysis Promotes Collagen Translation and Stability via α-Ketoglutarate-mediated mTOR Activation and Proline Hydroxylation.
    Ge J; Cui H; Xie N; Banerjee S; Guo S; Dubey S; Barnes S; Liu G
    Am J Respir Cell Mol Biol; 2018 Mar; 58(3):378-390. PubMed ID: 29019707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
    Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
    Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
    Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
    Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
    Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
    Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
    Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
    Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
    Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
    Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate.
    Wu B; Liu J; Zhao R; Li Y; Peer J; Braun AL; Zhao L; Wang Y; Tong Z; Huang Y; Zheng JC
    J Neuroinflammation; 2018 Mar; 15(1):79. PubMed ID: 29540215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
    BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
    Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
    Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.